Tobey J Betthauser1, Ansel T Hillmer2, Patrick J Lao3, Emily Ehlerding4, Jogeshwar Mukherjee5, Charles K Stone6, Bradley T Christian3. 1. Department of Medical Physics, University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA; Waisman Laboratory for Brain Imaging and Behavior, University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA. Electronic address: tbetthauser@wisc.edu. 2. Departments of Radiology and Biomedical Imaging, Psychiatry, Yale School of Medicine, New Haven, CT, USA. 3. Department of Medical Physics, University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA; Waisman Laboratory for Brain Imaging and Behavior, University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA. 4. Department of Medical Physics, University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA. 5. Preclinical Imaging, Department of Radiological Sciences, University of California - Irvine, Irvine, CA, USA. 6. Department of Medicine, University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA.
Abstract
INTRODUCTION: The α4β2* nicotinic acetylcholine receptor (nAChR) system is implicated in many neuropsychiatric pathologies. [18F]Nifene is a positron emission tomography (PET) ligand that has shown promise for in vivo imaging of the α4β2* nAChR system in preclinical models and humans. This work establishes the radiation burden associated with [18F]nifene PET scans in humans. METHODS: Four human subjects (2M, 2F) underwent whole-body PET/CT scans to determine the human biodistribution of [18F]nifene. Source organs were identified and time-activity-curves (TACs) were extracted from the PET time-series. Dose estimates were calculated for each subject using OLINDA/EXM v1.1. RESULTS: [18F]Nifene was well tolerated by all subjects with no adverse events reported. The mean whole-body effective dose was 28.4±3.8 mSv/MBq without bladder voiding, and 22.6±1.9 mSv/MBq with hourly micturition. The urinary bladder radiation dose limited the maximum injected dose for a single scan to 278 MBq without urinary bladder voiding, and 519 MBq with hourly voiding. CONCLUSIONS: [18F]Nifene is a safe PET radioligand for imaging the α4β2* nAChR system in humans. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE: This works presents human internal dosimetry for [18F]nifene in humans for the first time. These results facilitate safe development of future [18F]nifene studies to image the α4β2* nAChR system in humans.
INTRODUCTION: The α4β2* nicotinic acetylcholine receptor (nAChR) system is implicated in many neuropsychiatric pathologies. [18F]Nifene is a positron emission tomography (PET) ligand that has shown promise for in vivo imaging of the α4β2* nAChR system in preclinical models and humans. This work establishes the radiation burden associated with [18F]nifene PET scans in humans. METHODS: Four human subjects (2M, 2F) underwent whole-body PET/CT scans to determine the human biodistribution of [18F]nifene. Source organs were identified and time-activity-curves (TACs) were extracted from the PET time-series. Dose estimates were calculated for each subject using OLINDA/EXM v1.1. RESULTS: [18F]Nifene was well tolerated by all subjects with no adverse events reported. The mean whole-body effective dose was 28.4±3.8 mSv/MBq without bladder voiding, and 22.6±1.9 mSv/MBq with hourly micturition. The urinary bladder radiation dose limited the maximum injected dose for a single scan to 278 MBq without urinary bladder voiding, and 519 MBq with hourly voiding. CONCLUSIONS: [18F]Nifene is a safe PET radioligand for imaging the α4β2* nAChR system in humans. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE: This works presents human internal dosimetry for [18F]nifene in humans for the first time. These results facilitate safe development of future [18F]nifene studies to image the α4β2* nAChR system in humans.
Authors: Patrick J Lao; Tobey J Betthauser; Dana L Tudorascu; Todd E Barnhart; Ansel T Hillmer; Charles K Stone; Jogeshwar Mukherjee; Bradley T Christian Journal: Synapse Date: 2017-04-26 Impact factor: 2.562
Authors: Ansel T Hillmer; Dana L Tudorascu; Dustin W Wooten; Patrick J Lao; Todd E Barnhart; Elizabeth O Ahlers; Leslie M Resch; Julie A Larson; Alexander K Converse; Colleen F Moore; Mary L Schneider; Bradley T Christian Journal: Drug Alcohol Depend Date: 2014-02-15 Impact factor: 4.492
Authors: Kai Kendziorra; Henrike Wolf; Philipp Mael Meyer; Henryk Barthel; Swen Hesse; Georg Alexander Becker; Julia Luthardt; Andreas Schildan; Marianne Patt; Dietlind Sorger; Anita Seese; Herman-Josef Gertz; Osama Sabri Journal: Eur J Nucl Med Mol Imaging Date: 2010-11-11 Impact factor: 9.236
Authors: Hiroto Kuwabara; Yongjun Gao; Michael Stabin; Jennifer Coughlin; Sridhar Nimmagadda; Robert F Dannals; Martin G Pomper; Andrew G Horti Journal: Mol Imaging Biol Date: 2017-04 Impact factor: 3.488
Authors: Masahiro Fujita; Masanori Ichise; Christopher H van Dyck; Sami S Zoghbi; Gilles Tamagnan; Alexey G Mukhin; Ali Bozkurt; Nicholas Seneca; Dnyanesh Tipre; Christopher C DeNucci; Hidehiro Iida; D Bruce Vaupel; Andrew G Horti; Andrei O Koren; Alane S Kimes; Edythe D London; John P Seibyl; Ronald M Baldwin; Robert B Innis Journal: Eur J Nucl Med Mol Imaging Date: 2003-10-02 Impact factor: 9.236
Authors: Mathias Kranz; Bernhard Sattler; Solveig Tiepolt; Stephan Wilke; Winnie Deuther-Conrad; Cornelius K Donat; Steffen Fischer; Marianne Patt; Andreas Schildan; Jörg Patt; René Smits; Alexander Hoepping; Jörg Steinbach; Osama Sabri; Peter Brust Journal: EJNMMI Phys Date: 2016-10-21
Authors: Sang Hee Lee; Nunzio Denora; Valentino Laquintana; Giuseppe Felice Mangiatordi; Angela Lopedota; Antonio Lopalco; Annalisa Cutrignelli; Massimo Franco; Pietro Delre; In Ho Song; Hye Won Kim; Su Bin Kim; Hyun Soo Park; Kyungmin Kim; Seok-Yong Lee; Hyewon Youn; Byung Chul Lee; Sang Eun Kim Journal: Eur J Nucl Med Mol Imaging Date: 2021-11-16 Impact factor: 9.236